Adheris Inc. Files For Preliminary Injunction

barbara.lempert Adheris Inc. Files For Preliminary Injunction To Stop U.S. Government From Infringing On Constitutionally Protected Speech Lawsuit Seeks Relief from Unconstitutional ...

FDA staff plugs efficacy of projected COPD blockbuster from GSK and Theravance

Ryan McBride GlaxoSmithKline and partner Theravance are closing in on an important advisory committee meeting for their experimental lung drug Anoro Ellipta next week. And FDA staff ...

Celgene’s Abraxane approved for first-line treatment of pancreatic cancer

Eric Palmer The FDA today approved Celgene's Abraxane for pancreatic cancer, an approval that provides some hope for extending the lives of patients with the aggressive cancer. ...

Report Reviews Impact of Injectables on CMOs

mia.burns Injectable Dose Formulations Highly Impact Global Pharmaceutical Contract Manufacturing Vendor Revenues Frost & Sullivan finds several factors widening the fragmented ...

In big setback, GlaxoSmithKline’s cancer immunotherapy MAGE-A3 flunks PhIII goal

John Carroll GlaxoSmithKline experienced a major R&D setback today, reporting that its targeted cancer immunotherapy MAGE-A3 failed its first co-primary endpoint in a Phase III ...

Injectables jolt global contract manufacturing vendor revenue

mia.burns By Mia Burns The combination of cost benefits and a desire within the pharma industry to focus on core competencies has created an increasing need for outsourcing and spurred ...

Vivus CEO steps down citing health reasons

Alok Saboo FierceBiotech News

Sanofi bets on safer aspirin combos with $35M Pozen deal

Tracy Staton Sanofi is handing over a $ 15 million upfront payment along with promises of $ 20 million in precommercialization milestones. FiercePharma News

Analyst briefing details growth strategies within Russian healthcare market

mia.burns By Mia Burns Several fundamentals of the Russian healthcare industry continue to be strong, according to Frost & Sullivan. Large population base, growing middle class ...

Sanofi nabs U.S. rights to a safer aspirin in $35M Pozen deal

John Carroll Sanofi is handing over a $ 15 million upfront along with promises of $ 20 million in precommercialization milestones to partner with Chapel Hill, NC-based Pozen on a ...

Bristol-Myers moves jobs to Tampa to cut costs

Eric Palmer Bristol-Myers Squibb said last month it planned to consolidate some operations in the Hillsborough, FL, area. This week it announced it has leased a 70,000-square-foot ...

Troubled Rigel axes 30 staffers as it maps a comeback R&D strategy

John Carroll After a pair of painful setbacks in the clinic this year, South San Francisco-based Rigel Pharmaceuticals is axing 30 staffers and redirecting its R&D strategy in an ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS